Imexpharm Corporation reported VND2,205 billion (US$87.3 million) in net revenue for 2024, marking a 10.6% year-on-year increase.

HYTN will endeavour to amend its licenses and/or certificates, establish a stability program, and implement GMP-compliant processes tailored for vape cartridge production.

Imexpharm Corporation has announced its 2024 financial results with net revenue reaching VND2,205 billion, up 10.6 percent year on year, driven by robust growth in ETC channel and high-quality ...

Venus Remedies secures EU GMP renewal from Infarmed, strengthens European market presence: Our Bureau, Bengaluru Wednesday, January 22, 2025, 15:30 Hrs [IST] Venus Remedies has an ...